- More Upside if S&P Passes This Number: Market Pro
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- Why are Options Bullish on This Smartphone Maker?
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- 3 Hot Mid-Cap Stock Picks: Portfolio Manager
- 'Nice Opportunities' in Health Care Sector: Stock Picker
- Stocks To Play With Health Reform: Analysts
- 4 Tech Stocks For This Holiday Season: Analyst
MOST SHARED
- Bear Stearn Fund Managers Not Guilty on All Counts
- JPMorgan Chase to Hire 1,200 Mortgage Officers
- Fighting The Flu Vaccine Critics
- Hottest Zip Codes for Home Prices
- Oil Tomorrow
- Nov. 10: Unusual Volume Leaders
- Bair: Reserve Fund For Dismantling Must Be Set Up
- Commodity ETFs: Returns May Not Always Match Expectations
- A Squeeze on Customers Ahead of New Rules
- CNBC EXCLUSIVE: CNBC MEDIA ALERT: CNBC'S MARIA BARTIROMO SPEAKS WITH STARBUCKS CEO HOWARD SCHULTZ TODAY ON "CLOSING BELL"
- Farr: An Extended Period—No Fat Lady in Sight
- More Upside if S&P Passes This Number: Market Pro
- Murdoch Lashes Out At Google
- Fighting The Flu Vaccine Critics
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
- The Lloyd's Prayer
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- Three Things the US Can Do To Stop the Dollar's Decline
- Fed's Lacker: US in a 'Good Place' With Inflation
- Bear Stearn Fund Managers Not Guilty on All Counts
- Commodity ETFs: Returns May Not Match Expectations
- JPMorgan Chase to Hire 1,200 Mortgage Officers
- Home Prices Decline Further In Most Parts of US
- Ponzi Proceeds: Bidding on Madoff's Toys
- Quiz: Do You Know Your Coca-Cola Myths?
- UBS Faces Roadblock in Poaching More BofA Talent
RSS FEED
CNBC Stock Blog
Text Size 
Deals may have slowed down, but M&A ain't dead.
Big mergers and acquisitions across sectors including biotech and pharma, tech, materials and manufacturing are coming to pass. And high-profile combinations including Roche and Genentech [DNA
Loading...
()
], Dow Chemical [DOW
Loading...
()
] and Rohm & Haas [ROH
Loading...
()
] are expected to close soon.
Roche finally has a sufficient war chest of "enormous amounts of capital" which it raised in the U.S. and Europe, reports CNBC's David Faber. The Swiss drug maker now holds 93.2 percent of Genentech, with 3 percent of the latter's outstanding shares "guaranteed to be delivered within three business days."
Watch the video above for Faber's full report.
_________________________________
More from CNBC:
_________________________________
_________________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes